Plain-English translation of NCT07612774 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether , a powerful cholesterol-lowering medication, can better slow the buildup of plaque in your heart arteries compared to standard cholesterol drugs alone. You've already had a stent placed during your heart attack treatment, and this trial will follow you for one year to see if the medication helps prevent plaque from getting worse in other arteries.
Even after a heart attack and stent placement, many patients still develop more plaque buildup in other arteries, which raises the risk of future heart problems. Researchers want to know if this stronger medication can reduce that risk better than current standard treatment.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll be randomly assigned to either receive the new medication along with your regular cholesterol drugs, or to continue with standard cholesterol treatment alone. Both groups will have heart imaging scans (a special CT scan) at the beginning and again after 52 weeks to see how your arteries are doing. You'll also have blood tests to check your cholesterol levels and inflammatory markers throughout the year.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China